Stifel Nicolaus Boosts Zymeworks (NASDAQ:ZYME) Price Target to $47.00

Zymeworks (NASDAQ:ZYME) had its price objective hoisted by equities researchers at Stifel Nicolaus from $40.00 to $47.00 in a research note issued to investors on Tuesday,Benzinga reports. The firm presently has a “buy” rating on the stock. Stifel Nicolaus’ price objective would suggest a potential upside of 86.29% from the stock’s current price.

Several other analysts also recently issued reports on ZYME. B. Riley Financial reissued a “buy” rating and set a $40.00 target price (up from $30.00) on shares of Zymeworks in a research note on Friday, November 21st. Wall Street Zen lowered shares of Zymeworks from a “buy” rating to a “hold” rating in a report on Saturday, November 8th. Leerink Partners lifted their price objective on shares of Zymeworks from $52.00 to $58.00 and gave the company an “outperform” rating in a research report on Tuesday. Zacks Research cut shares of Zymeworks from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, November 26th. Finally, Citigroup assumed coverage on shares of Zymeworks in a report on Wednesday, December 3rd. They issued an “outperform” rating on the stock. Two equities research analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Zymeworks currently has an average rating of “Moderate Buy” and an average price target of $35.70.

Zymeworks Price Performance

ZYME stock opened at $25.23 on Tuesday. Zymeworks has a 1 year low of $9.03 and a 1 year high of $28.49. The company has a market cap of $1.86 billion, a P/E ratio of -23.36 and a beta of 1.23. The stock’s fifty day moving average price is $23.82 and its 200-day moving average price is $20.98.

Zymeworks (NASDAQ:ZYME) last announced its earnings results on Monday, March 2nd. The company reported ($0.55) EPS for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.20). Zymeworks had a negative return on equity of 26.00% and a negative net margin of 76.56%.The company had revenue of $2.52 million during the quarter, compared to the consensus estimate of $21.78 million. During the same period in the prior year, the business posted ($0.31) earnings per share. Zymeworks’s revenue for the quarter was down 91.9% compared to the same quarter last year.

Insiders Place Their Bets

In other Zymeworks news, CEO Kenneth Galbraith sold 30,424 shares of the firm’s stock in a transaction dated Monday, January 12th. The stock was sold at an average price of $22.67, for a total value of $689,712.08. Following the transaction, the chief executive officer directly owned 226,842 shares of the company’s stock, valued at $5,142,508.14. This trade represents a 11.83% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, COO Mark Hollywood sold 6,120 shares of the company’s stock in a transaction dated Monday, January 12th. The stock was sold at an average price of $22.67, for a total value of $138,740.40. Following the completion of the sale, the chief operating officer directly owned 132,913 shares of the company’s stock, valued at $3,013,137.71. The trade was a 4.40% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 187,933 shares of company stock worth $4,673,716 over the last ninety days. Company insiders own 33.51% of the company’s stock.

Institutional Trading of Zymeworks

A number of hedge funds and other institutional investors have recently made changes to their positions in ZYME. Optiver Holding B.V. bought a new stake in shares of Zymeworks during the 3rd quarter worth about $26,000. Caitong International Asset Management Co. Ltd acquired a new stake in Zymeworks in the fourth quarter worth approximately $37,000. Quarry LP bought a new position in Zymeworks during the 3rd quarter valued at $50,000. Tower Research Capital LLC TRC raised its stake in shares of Zymeworks by 29.6% in the 2nd quarter. Tower Research Capital LLC TRC now owns 4,947 shares of the company’s stock worth $62,000 after buying an additional 1,131 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. raised its stake in shares of Zymeworks by 25.2% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,637 shares of the company’s stock worth $96,000 after buying an additional 731 shares in the last quarter. Institutional investors own 92.89% of the company’s stock.

Zymeworks News Roundup

Here are the key news stories impacting Zymeworks this week:

• Positive Sentiment: Several firms raised price targets and ratings, boosting upside expectations (Stifel Nicolaus to $47 buy; Leerink Partners to $58 outperform). Analyst upgrades raise demand and support a higher valuation. Benzinga: Price Target Raises
• Positive Sentiment: Zymeworks closed a $250M royalty-backed financing with Royalty Pharma and reported $270.6M in cash — extending the runway beyond 2028 and materially lowering near-term dilution risk, which investors favor for biotech developers. Seeking Alpha: FY25 Review
• Positive Sentiment: Consensus analyst stance remains constructive (average “Moderate Buy”), lending continued buy-side support amid the company’s milestone-driven story. AmericanBankingNews: Analyst Recommendation
• Neutral Sentiment: Company and sell-side coverage provided detailed Q4 call transcripts and summaries — useful for modeling but mixed in tone (operational detail, milestone runway, commercialization planning). Investors will parse these for near-term catalysts. Yahoo Finance: Q4 Earnings Call Summary
• Neutral Sentiment: Management outlined a milestone-driven expansion through 2028 with stated ~$1.5B potential in milestones — a roadmap that can create big upside but depends on successful execution and commercial launches. Seeking Alpha: Milestone Potential
• Negative Sentiment: Q4 results were a clear downside: EPS and revenue materially missed estimates (revenue fell ~92% YoY), and margins remain negative — highlighting execution risk and the milestone volatility inherent in the business. This weakness remains a fundamental headwind until commercial traction is demonstrated. Yahoo Finance: Q4 Earnings Transcript
• Negative Sentiment: The company’s improved liquidity increases upside optionality but also concentrates investor returns on the commercial success of Ziihera/zanidatamab — meaning trial/commercial execution risk could trigger downside if launches underperform. Seeking Alpha: FY25 Review

About Zymeworks

Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. The company specializes in engineered antibody and protein therapeutics designed to address a range of unmet medical needs in oncology and other serious diseases. Through its proprietary platforms, Zymeworks aims to create novel bispecific and multispecific molecules that can simultaneously engage multiple targets and recruit immune effector functions to enhance potency and specificity.

At the core of Zymeworks’ innovation is its Azymetric™ bispecific antibody platform, which enables the design of asymmetrical bispecific antibodies with controlled assembly and high stability.